Sumitomo Mitsui DS Asset Management Company Ltd Has $22.11 Million Holdings in Stryker Co. (NYSE:SYK)

Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in shares of Stryker Co. (NYSE:SYK) by 4.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,394 shares of the medical technology company’s stock after acquiring an additional 2,868 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Stryker were worth $22,105,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dunhill Financial LLC raised its holdings in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares during the last quarter. Darwin Wealth Management LLC bought a new position in Stryker during the third quarter worth about $36,000. Crews Bank & Trust bought a new position in shares of Stryker in the fourth quarter valued at approximately $39,000. Hara Capital LLC bought a new position in shares of Stryker in the third quarter valued at approximately $42,000. Finally, Grove Bank & Trust raised its stake in Stryker by 84.8% in the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock valued at $44,000 after purchasing an additional 56 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Trading Down 0.7 %

SYK opened at $396.24 on Friday. The stock has a market capitalization of $151.06 billion, a PE ratio of 51.06, a P/E/G ratio of 2.78 and a beta of 0.96. The firm’s fifty day moving average price is $377.08 and its 200 day moving average price is $364.24. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the firm posted $3.46 earnings per share. As a group, research analysts expect that Stryker Co. will post 13.5 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.85%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on SYK shares. Citigroup lifted their target price on shares of Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Evercore ISI boosted their target price on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. BTIG Research upped their price target on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Robert W. Baird boosted their price objective on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, JMP Securities restated a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $419.37.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 5.50% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.